Though further studies are warranted to assess effects on long-term outcomes, their documented role in reducing infections suggests that there may yet be a role for G-CSF/GM-CSF as one element of a multidrug treatment in combination with other immunotherapies. This evidence concerns the gene CSF2 and infection.